Search Results: type 2 diabetes (243)

What is MS? Multiple sclerosis (MS) is a mysterious and frequently distressing disease. MS affects the brain and spinal cord,…

Health Sciences Authority (HSA) is Singapore’s national authority regulating health products, including medications. Every month, HSA publishes a list of…

Everyone knows what diabetes is, but what about the complications of diabetes? The Journal of Diabetology, in its 2018 edition,…

A recent publication in JAMA Ophthalmology has brought to light potential risks associated with the use of semaglutide, a medication often prescribed for managing type 2 diabetes (T2D) and obesity.

The weight-loss drug Ozempic is well-known for its effectiveness in managing type 2 diabetes and aiding significant weight loss. Additionally, it has recently been linked to unexpected pregnancies and new health benefits. Several women reported surprise pregnancies after using the drug. Concurrently, recent studies also suggest Ozempic could reduce the risk of kidney disease progression in diabetic patients.

With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

Ozempic injection – a once-weekly noninsulin medicine developed by Novo Nordisk that helps blood sugar control in adults with type 2 diabetes.

The introduction of CGM devices has revolutionalised the management of both Type 1 and Type 2 diabetes with fewer fingerstick tests.

The tragic case of the death of a resident doctor due to alleged bullying at Diponegoro University is a serious challenge facing the medical world in Indonesia. 

On 11 August 2024, the Director of Nutrition and Maternal and Child Health, dr. Lovely Daisy, MKM, announced that this regulation prohibits the promotion of formula milk, which is stipulated in Article 33, as part of efforts to increase the success of exclusive breastfeeding in Indonesia. The regulation adopts the International Code of Marketing of Breast-milk Substitutes that has been introduced by the World Health Organisation (WHO) since 1981.